Most researchers who hit a plateau reach for a stronger compound. Research suggests the reason a protocol stalls is almost never the compound. It is the diagnosis.
For educational and research purposes only. This is not medical advice and is not human-use guidance. Consult a qualified professional before acting on anything here.
Start here
Fat loss stalls for two reasons. Intake control fails, or output capacity fails. These are completely different problems. They produce different symptoms and they call for completely different compounds, and using the wrong tool for the wrong problem does not produce nothing. It often makes things worse.
The question that determines every rational protocol decision is not which compound is strongest. It is which side is currently the limiting variable, meaning the one thing that is actually holding the result back right now. Everything downstream in this guide depends on getting that one read right first.
Intake side means appetite control is the problem. Food is always on your mind, hunger is loud, meals do not satisfy, and the scale has never moved consistently. Output side means intake is already handled and something else has stalled. The deficit is confirmed, but the scale slowed weeks ago, energy is declining week over week, training is dropping off, and recovery is stretching out.
Appetite is the limiting variable
Always thinking about food. Physically hungry despite eating enough. Cravings loud and evenings a negotiation. Meals do not satisfy. Food noise constant through the day. The scale has never moved consistently.
Capacity is the limiting variable
Intake controlled and the deficit confirmed. Scale slowed or stopped weeks ago. Energy declining week over week. Training performance dropping. Recovery extending between sessions. Working harder for the same or worse results.
This is the part a PDF could not do. Read each signal below and pick the side that matches your current situation. The tally underneath updates as you go, and it points at which side to read for, not at a compound. It returns a read on where the limiting variable most likely sits, and nothing here saves or leaves your device on this first section.
Escalating an intake compound when the problem is on the output side does not increase fat loss. Research suggests it reduces energy output faster than it improves restriction.
Researchers who confuse these two make a specific mistake. They see the scale slow, assume the intake compound stopped working, and escalate. What that actually does is increase suppression when the problem is no longer suppression, and the body responds by conserving energy faster. Output drops further and the plateau holds. The rest of this framework is built to keep that mistake from happening, starting with the four inputs that sit underneath every compound.
Free — no payment required
The remaining sections cover the four foundation inputs that gate every compound, the three output failure patterns, phase logic, the three questions to work through before any protocol change, and the compounds on each side in plain language. Enter your email to unlock them. One step, no account needed.
No spam. Used only for research guide access and occasional protocol updates from Project Theo.
Part two
Compounds amplify what is already present. They do not replace a broken foundation. Four inputs sit underneath every metabolic compound, and if any one of them is failing, that input is the first thing to address, not a compound. No compound bypasses a broken foundation, and addressing the gate first is not optional.
Sleep is the first input. Six or more hours of consistent quality. When it fails, a stress hormone called cortisol rises, oxidative stress climbs, and the mitochondria, which are the parts of the cell that produce energy, cannot function. Every metabolic compound underperforms regardless of dose.
Stimulant load is the second. The target is not depending on stimulants to reach a baseline level of energy. Daily stimulants raise cortisol and oxidative stress, so the researcher damages the mitochondria while trying to support them. Capacity declines and the damage accelerates.
Stress and cortisol is the third. Cortisol not chronically elevated. Cortisol sets the ceiling for what any compound can accomplish, because it directly opposes fat mobilization, impairs sleep, and degrades the mitochondrial membrane. Research suggests most plateaus have a cortisol ceiling underneath them.
Training stimulus is the fourth. Consistent resistance training three to four times a week. Peptides, which are short chains of amino acids that act as signals in the body, amplify signals. Without a training signal, growth hormone compounds have almost nothing to protect, and without adaptation demand, metabolic compounds have almost nothing to amplify.
Check the inputs that are genuinely in place right now. The read at the bottom updates as you go and saves to this device, so a researcher who fixes their sleep in three weeks can come back and see the picture change. This returns a read on your foundation. It does not return a compound.
Nothing checked yet. Work through the four inputs above and a read will appear here.
Why this comes before the patterns. A broken foundation input and a genuine output failure can look identical from the scale alone. Ruling out the four inputs first is the cheaper move and the more common fix, which is why it sits ahead of everything that follows.
Part three
When the output side fails, it fails in specific patterns. Identifying which pattern is present is what determines which question is even worth asking next. Two of these patterns call for opposite responses, so reading the wrong one does not produce nothing. It can make energy worse.
Pattern one is a fuel switching failure. Energy crashes hard between meals, peaks after eating, and depends on stimulants. The mitochondria cannot switch from burning glucose to burning fat when glucose runs out. A signal called AMPK, which acts as the cell's metabolic rate sensor, is blunted. The fuel is available but the cells cannot access it.
Pattern two is membrane damage. Energy is consistently flat regardless of food timing, not a crash and recover cycle but a depleted baseline, with recovery stretching to two or three days. The inner membrane of the mitochondria has taken oxidative damage from prolonged restriction, poor sleep, stimulant history, or elevated cortisol, and energy leaks at the membrane level.
Pattern three is a stimulant trap. Low energy drives stimulant escalation, which gives a temporary boost followed by deeper fatigue, and the cycle repeats. The stimulants raise cortisol and oxidative stress, which damages the mitochondria further, so more stimulants are needed. Here the lifestyle input is the variable, not a compound.
Pick the option in each row that matches what you actually experience. The tally reads your pattern against the two that a compound question can even apply to. Where your answers point clearly, part five will carry a labelled suggestion you can confirm or override. This returns a pattern, not a compound.
The distinction that matters. Pattern one is about how existing fuel is accessed. Pattern two is about a membrane that is leaking energy. These solve different problems, and adding demand to a system in Pattern two makes energy worse rather than better. If a stimulant trap is the honest read, the lifestyle input is the intervention, which is why the tally above only weighs the two a compound question can address.
Part four
Compound selection without phase awareness is guesswork. The right compound in the wrong phase is not a neutral move, and research suggests it often makes the limiting variable worse rather than better. This is reference you look your own situation up in, so it is a table rather than prose.
| Phase | Limiting variable | Signals that confirm it | What research supports here | What tends to backfire |
|---|---|---|---|---|
| Phase 1, weeks 1 to 8 | Intake | Scale moving, appetite suppressed, energy stable | A GLP-1 or dual agonist, with lean mass support from week 4, and a repair peptide such as BPC-157 if joint stress is present | Output or growth hormone compounds, which add complexity before it is needed |
| Phase 2, weeks 6 to 16 | Metabolism adapting | Intake controlled, scale slowed, energy beginning to fall, training output dropping | A caloric audit first, then a coenzyme called NAD+, then a Pattern 1 fuel access compound, or an AMPK reactivator if both energy and fat loss stall together, with a growth hormone layer for lean mass | Escalating a GLP-1 dose, or adding a membrane compound before Phase 3 is confirmed |
| Phase 3, weeks 12 and beyond | Mitochondrial efficiency | Flat energy regardless of food, recovery extending, fatigue on rest days | Fixing sleep and stimulant load first, then NAD+, then a membrane stabiliser for Pattern 2, and scaling back training volume | A fuel access compound, thermogenics, or anything that adds metabolic demand to a depleted system |
NAD+ is always the foundation before any output compound. It is the substrate the mitochondria use to produce energy, and running the tools without the substrate limits both.
One sequencing rule runs across every phase. NAD+ is the substrate the mitochondria use, and the output compounds are the tools that act on top of it. Running the tools without the substrate limits both, and research suggests this is the most common sequencing error in output protocols. Knowing which phase you are in is what makes the next section's questions answerable rather than a guess.
How to read this table. The phase windows overlap on purpose, because they are defined by the limiting variable and its signals rather than by the calendar. Match the signals column to what you are seeing rather than counting weeks, and treat the last two columns as the framework's general direction, not as instructions for your specific protocol.
Part five
Before escalating a dose, adding a compound, or switching anything, research suggests working through these three questions in order. Each one narrows what needs to change, and they do not return a compound verdict. They return the variable worth looking at next, which is what keeps this a framework rather than a recommendation. Your answers save on this device.
These three questions do not guarantee a diagnosis. What they do is eliminate the most common reasons a protocol change fails before it starts. The variable you identify today is only useful if you check whether it moved, so save this read with a date, come back in four to six weeks, and log another. The entries stay on this device.
Where this framework reaches its limit. If all three questions come back clean and the stall persists, the problem is specific to your situation, and a generic framework has reached its edge. Nothing here resolves an individual protocol. It narrows which variable is worth looking at next without knowing your bloodwork, your training load, or your history, and that limit is worth stating plainly.
Part six
Intake compounds change the eating experience through the brain and the gut. The scale moves because calories are naturally lower, not because anything is being burned differently. The question before selecting or escalating one is whether appetite is actually the limiting variable right now. These are reference tables you look your own situation up in.
| Intake compound | Mechanism in plain language | Suited to this phase | Does not address this |
|---|---|---|---|
| Semaglutide | Slows stomach emptying, increases early fullness, reduces food noise. Works through one receptor and has the longest research track record in this class. | Scale not yet moving, appetite and food noise the primary complaint, a first compound in this category | An output stall where the deficit is confirmed. It works on intake, not on a metabolism that has adapted. |
| Tirzepatide | Everything semaglutide does, plus a second receptor called GIP that improves how the body handles incoming nutrients and insulin signaling. | A primary fat loss goal where the dual receptor mechanism is the priority, and where GI tolerability has been better for some researchers | An output or efficiency stall. Adding more intake suppression does not fix a metabolism problem. |
| Retatrutide | Three receptors, GLP-1 plus GIP plus glucagon. The glucagon signal tells the liver to release stored energy and raises resting metabolic rate, adding thermogenesis, meaning the body generating heat as a way of burning energy. | A plateau on semaglutide or tirzepatide at a therapeutic dose, in Phase 2 where thermogenesis is the mechanism the situation calls for | Pure appetite suppression matched to a single agonist. The glucagon component behaves differently depending on how it is dosed, which research treats as part of the mechanism rather than a fault. |
| Tesofensine | Works through brain neurochemistry, dopamine, noradrenaline and serotonin, rather than gut hormones. Increases drive and focus alongside appetite control and requires movement to work. | Already training consistently, needs mental drive alongside appetite control, found the GLP-1 response too passive | A sedentary starting point or a high cardiovascular stress baseline. Combining it with retatrutide creates extreme suppression. |
| Cagrilintide | Adds satiety through the amylin receptor, a separate pathway from GLP-1. It does not add more GLP-1 suppression, it extends how long satiety lasts. | On semaglutide at a therapeutic dose where appetite pressure is still insufficient and more satiety is wanted without switching compounds | A stall on retatrutide, which research suggests is usually on the output side. Adding satiety there is the wrong diagnosis. |
One distinction on retatrutide. The glucagon component drives physical hunger while the GLP-1 component suppresses food noise at the same time. Both signals being present at once means the mechanism is working as designed, not that something is wrong. Judging retatrutide by hunger alone misreads how it works.
Output compounds work on mitochondrial capacity, how much energy the body can produce and how efficiently it uses fuel. They do not address hunger, and they belong in a completely different phase from intake compounds. The table below sets them out the same way, by the job each does.
| Output compound | Mechanism in plain language | Phase and pattern | The critical note |
|---|---|---|---|
| NAD+ | The primary coenzyme, meaning a helper molecule, that mitochondria use to convert food into ATP, which is the energy the cells actually run on. It declines with age and sustained restriction. | Phase 2 to 3, always added before the tools, both patterns require it | This is the substrate. The other output compounds are the tools. Running the tools without the substrate limits both. |
| MOTs-c | Activates AMPK, the metabolic rate sensor, and restores the ability to switch from burning glucose to burning fat. It improves fuel access, not fuel production. | Phase 2 only, Pattern 1 only, meal-dependent crashes that recover with food | If energy gets worse after adding it, that is the most reliable Phase 3 signal available. It means the engine is damaged, not just inefficient. |
| SS-31 | Stabilises the inner mitochondrial membrane, the layer where oxidative damage causes energy to leak. It works by stopping the leak, not by producing more energy. | Phase 3 only, Pattern 2 only, flat energy regardless of food and extended recovery | It does not feel like anything. No acute sensation is the correct mechanism. Measure it by recovery time and training performance at six to eight weeks. |
| AICAR | Reactivates AMPK through a different pathway than MOTs-c, resetting the metabolic rate sensor when the MOTs-c pathway has not resolved a stall. | Phase 2, when both energy and fat loss have stalled together and NAD+ plus MOTs-c have not resolved it | Not a first-line output compound. NAD+ and MOTs-c come first, and it does not belong in Phase 3. |
| 5-Amino-1MQ | Removes a metabolic brake inside fat cells during restriction by inhibiting an enzyme called NNMT that slows energy recycling. Oral, and a silent compound. | Early Phase 2, when appetite is newly controlled and metabolism is still responsive, before deeper adaptation | It does not produce a felt sensation. The benefit is structural and shows in body composition at eight to twelve weeks, which is why it is the most commonly abandoned compound that was actually working. |
Where this guide stops. This guide covers the diagnostic logic, the two categories, the foundation gate, the patterns, phase sequencing and the three questions. What it does not cover is the compound-level detail of the exact signs something is working or off, the full stack compatibility rules, and the phase-by-phase decision paths. Those are what the diagnostic tools and the Protocol Audit are built to work through, and knowing the diagnosis is what makes them worth using.
Take it with you
The page is the current version and reflects the framework as it stands now. The PDF is the takeaway if you want it offline.
Next step
The Protocol Tool is a free diagnostic that reads your situation and points you at the one guide built for it, so the read you just worked through becomes a specific place to go rather than a general direction. If you would rather browse, the full free guide catalog covers each compound decision, stacking question and protocol framework on its own.
